The adenylate cyclase toxin-hemolysin (CyaA) of Bordetella pertussis is a bi-functional leukotoxin. It penetrates myeloid phagocytes expressing the complement receptor 3 and delivers into their cytosol its N-terminal adenylate cyclase enzyme domain (~400 residues). In parallel, ~1300 residue-long RTX hemolysin moiety of CyaA forms cation-selective pores and permeabilizes target cell membrane for efflux of cytosolic potassium ions. The non-enzymatic CyaA-AC(-) toxoid, has repeatedly been successfully exploited as an antigen delivery tool for stimulation of adaptive T-cell immune responses. We show that the pore-forming activity confers on the CyaA-AC(-) toxoid a capacity to trigger Toll-like receptor and inflammasome signaling-independent maturation of CD11b-expressing dendritic cells (DC). The DC maturation-inducing potency of mutant toxoid variants in vitro reflected their specifically enhanced or reduced pore-forming activity and K(+) efflux. The toxoid-induced in vitro phenotypic maturation of DC involved the activity of mitogen activated protein kinases p38 and JNK and comprised increased expression of maturation markers, interleukin 6, chemokines KC and LIX and granulocyte-colony-stimulating factor secretion, prostaglandin E2 production and enhancement of chemotactic migration of DC. Moreover, i.v. injected toxoids induced maturation of splenic DC in function of their cell-permeabilizing capacity. Similarly, the capacity of DC to stimulate CD8(+) and CD4(+) T-cell responses in vitro and in vivo was dependent on the pore-forming activity of CyaA-AC(-). This reveals a novel self-adjuvanting capacity of the CyaA-AC(-) toxoid that is currently under clinical evaluation as a tool for delivery of immunotherapeutic anti-cancer CD8(+) T-cell vaccines into DC.

Department of Pneumology and BIOSS Albert Ludwig University Freiburg Germany

Faculty of Science Charles University Prague Czech Republic

INSERM U1041 Paris France

Institut Pasteur Unité de Régulation Immunitaire et Vaccinologie Paris France

Institute of Microbiology of the ASCR v v i Prague; Czech Republic

Sotio a s Prague Czech Republic

Zobrazit více v PubMed

Curr Pharm Biotechnol. 2012 Jun;13(8):1446-73 PubMed

Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):10995-1000 PubMed

J Immunol. 2005 Apr 1;174(7):4295-300 PubMed

J Dermatol Sci. 2006 Apr;42(1):1-11 PubMed

Blood. 2002 Aug 15;100(4):1354-61 PubMed

J Immunol Methods. 1999 Feb 1;223(1):77-92 PubMed

Int J Mol Med. 2003 Jul;12(1):83-6 PubMed

Infect Immun. 2003 Oct;71(10):6058-62 PubMed

J Immunol. 2014 Aug 15;193(4):1787-98 PubMed

Nat Immunol. 2001 Apr;2(4):346-52 PubMed

J Immunol. 2000 Oct 15;165(8):4272-80 PubMed

J Cell Mol Med. 2011 Apr;15(4):938-48 PubMed

PLoS Pathog. 2008 Oct;4(10 ):e1000176 PubMed

J Biol Chem. 1999 Dec 31;274(53):37644-50 PubMed

Immunity. 1998 Jul;9(1):143-50 PubMed

J Exp Med. 2001 May 7;193(9):1035-44 PubMed

J Immunol. 1996 Jun 15;156(12):4697-706 PubMed

Mol Microbiol. 2010 Mar;75(6):1550-62 PubMed

Vaccine. 2004 Oct 22;22(31-32):4270-81 PubMed

FASEB J. 2009 Sep;23(9):2831-43 PubMed

J Biol Chem. 2001 Jan 5;276(1):125-32 PubMed

Int J Med Microbiol. 2004 Apr;293(7-8):571-6 PubMed

Int Immunol. 2005 Sep;17(9):1201-12 PubMed

Trends Microbiol. 2014 Feb;22(2):49-52 PubMed

J Virol. 2005 Aug;79(15):9872-84 PubMed

Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12532-7 PubMed

J Immunol. 2010 Aug 1;185(3):1711-9 PubMed

Cell Death Differ. 2007 Jan;14(1):10-22 PubMed

Infect Immun. 2000 Jan;68(1):247-56 PubMed

J Immunol. 2001 Mar 15;166(6):3837-45 PubMed

Immunity. 2008 Sep 19;29(3):325-42 PubMed

J Immunol. 2006 Jul 1;177(1):70-6 PubMed

J Biol Chem. 2003 Oct 3;278(40):38514-21 PubMed

J Biol Chem. 2007 Feb 2;282(5):2808-20 PubMed

Annu Rev Immunol. 2002;20:55-72 PubMed

Cell Microbiol. 2011 Jul;13(7):1026-43 PubMed

Immunity. 2006 Mar;24(3):317-27 PubMed

Nat Immunol. 2003 Dec;4(12):1223-9 PubMed

Blood. 2000 Aug 1;96(3):1039-46 PubMed

Infect Immun. 1995 Oct;63(10):3851-7 PubMed

Vaccine. 2007 Jan 2;25(1):64-71 PubMed

Infect Immun. 2006 Apr;74(4):2207-14 PubMed

Infect Immun. 2006 Dec;74(12):6797-805 PubMed

Anal Biochem. 2014 Apr 1;450:57-62 PubMed

Biochemistry. 2005 Sep 27;44(38):12759-66 PubMed

Annu Rev Immunol. 2000;18:767-811 PubMed

Int Immunol. 2003 Dec;15(12):1423-30 PubMed

Am J Physiol Cell Physiol. 2011 Jun;300(6):C1205-14 PubMed

J Immunol. 1997 Sep 1;159(5):2452-61 PubMed

Curr Opin Microbiol. 2006 Feb;9(1):69-75 PubMed

PLoS Pathog. 2010 May 13;6(5):e1000901 PubMed

Springer Semin Immunopathol. 2005 Jan;26(3):273-87 PubMed

Microb Pathog. 1992 Mar;12(3):227-35 PubMed

J Exp Med. 2010 Nov 22;207 (12 ):2609-19 PubMed

Infect Immun. 1990 Oct;58(10):3445-7 PubMed

J Immunol. 2008 Nov 15;181(10):6803-9 PubMed

PLoS Pathog. 2012;8(4):e1002580 PubMed

Biochem Biophys Res Commun. 2009 Aug 7;385(4):503-6 PubMed

Int Immunol. 2004 Dec;16(12 ):1701-9 PubMed

PLoS Pathog. 2011 Mar;7(3):e1001314 PubMed

Nat Rev Immunol. 2002 Mar;2(3):151-61 PubMed

PLoS Pathog. 2013;9(4):e1003264 PubMed

J Exp Med. 1998 Dec 7;188(11):2175-80 PubMed

Delivery of Mycobacterium tuberculosis epitopes by Bordetella pertussis adenylate cyclase toxoid expands HLA-E-restricted cytotoxic CD8+ T cells

The Fim and FhaB adhesins play a crucial role in nasal cavity infection and Bordetella pertussis transmission in a novel mouse catarrhal infection model

Kingella kingae RtxA Cytotoxin in the Context of Other RTX Toxins

Structure-Function Relationships Underlying the Capacity of Bordetella Adenylate Cyclase Toxin to Disarm Host Phagocytes

Invasion of Dendritic Cells, Macrophages and Neutrophils by the Bordetella Adenylate Cyclase Toxin: A Subversive Move to Fool Host Immunity

Cyclic AMP-Elevating Capacity of Adenylate Cyclase Toxin-Hemolysin Is Sufficient for Lung Infection but Not for Full Virulence of Bordetella pertussis

Negatively charged residues of the segment linking the enzyme and cytolysin moieties restrict the membrane-permeabilizing capacity of adenylate cyclase toxin

Bordetella adenylate cyclase toxin: a unique combination of a pore-forming moiety with a cell-invading adenylate cyclase enzyme